358,664 353,790 2,767,409 965,000
Depreciation of property,
plant and equipment and
amortization of licenses
and permits 233,502 165,750 749,619 640,568
Total operating expense 4,636,388 2,992,058 20,979,702 13,564,066
Operating income 3,107,741 3,294,753 15,580,861 13,474,793
Interest and financing
expenses (45,859) (183,779) (701,637) (478,436)
Interest income and
other income
(expenses) 327,248 (110,633) 290,563 190,668
Income before income
taxes and minority
interest 3,480,848 3,000,341 15,169,787 13,187,025
Income taxes recovery
(expense)
- Current 788,445 (330,229) (3,441,168) (2,203,173)
- Deferred (504,450) 287,751 487,011 229,055
Income before minority
interest 3,764,843 2,957,863 12,215,630 11,212,907
Minority interest share
of earnings 1,390,704 964,588 4,205,407 3,562,501
Net income 2,374,139 1,993,275 8,010,223 7,650,406
Other comprehensive
income
Foreign currency
translation adjustment (467,232) 513,502 1,816,769 1,310,985
Comprehensive income $2,276,907 $2,506,777 $10,196,992 $8,961,391
Earnings per share
- Basic $0.06 $0.05 $0.19 $0.19
- Diluted $0.06 $0.05 $0.19 $0.19
Weighted average number
of shares of common
stock outstanding
- Basic 42,892,954 40,268,030 42,426,703 40,243,657
- Diluted 42,892,954 40,624,439 42,450,606 40,523,937
SINOVAC BIOTECH LTD.
Consolidated Statements of Cash Flows
Three Months and
'/>"/>SOURCE Sinovac Biotech Ltd. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Related biology technology :1.
Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results2.
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results3.
Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status4.
Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility5.
Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine6.
Sinovac Releases Statement on Healive Vaccine Suspension7.
Sinovac Reports Third Quarter 2008 Unaudited Financial Results8.
Sinovac Named to Deloitte Technology Fast 50 China9.
Sinovac to Participate in Two Upcoming Investor Conferences10.
Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating11.
Sinovac Biotech Holds 2007 Annual General Meeting